

REMARKS

Claims 1 - 43 are pending in the application. The objection of the Draftsperson to the drawings has been noted. Amended drawings will be submitted on receipt of notification of allowance of a claim. The following is in response to the Examiner's restriction and requirement for election.

Election/Restriction


In response to the Examiner's requirement for restriction under 35 USC 121, without prejudice and in the interests of facilitating prosecution, applicant elects Group 1 consisting of claims 1-15, 23, 25, 26, 34-40, and 43 drawn to a method of making a pharmacophore model of CYP2D6 inhibitor potency of SSRI compounds, classified in class 702 subclass 27, with traverse.

In accord with the Examiner's requirement to elect a single disclosed species, applicant elects the species of Example 2.

The applicant respectfully submits that the pending claims are fully allowable, and solicits the issuance of a notice to such effect. If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicants' undersigned attorney at the telephone number provided.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date: June 18, 2004



A. David Joran
Attorney for Applicant(s)
Reg. No. 37,858

Pfizer Inc
Patent Department
150 East 42nd Street - 5th Floor
New York, NY 10017-5755
(212) 733-3381